![]() ![]() The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. Under no circumstances does any information posted on represent a recommendation to buy or sell a security. Is not operated by a broker, a dealer, or a registered investment adviser. The firm's customers include enterprise, commercial and industrial, electric cooperatives, project developers, utilities, solar engineering, procurement and construction (EPCs), and independent power producers (IPPs) and asset owners. Its solutions include energy storage, solar plus storage, wholesale energy markets, microgrids, backup power and voltage support, utility bill optimization, demand response and commercial electronic vehicle (EV) charging. Stem's energy software platform, Athena, is an artificial intelligence (AI)-powered analytics platform that enables customers and partners to optimize energy use by automatically switching between battery power, onsite generation and grid power. ![]() The company also enagaged in offering clean energy intelligence and optimization. The firm is focused on providing smart energy storage and energy management software. The company is headquartered in San Francisco, California and currently employs 213 full-time employees. builds and operates the digitally connected energy storage network. The drug candidate is set to become the first ever CRISPR-based treatment approved for the US market later this year.Stem, Inc. Vertex and its partner CRISPR Therapeutics have received validations from the European Medicines Agency and from UK authorities for filings concerning product candidate exagamglogene autotemcel, formerly known as CTX001, as a one-time treatment for severe sickle cell disease and transfusion-dependent beta thalassemia. ![]() VCTX210 is an investigational, gene-edited, immune-evasive, allogeneic stem cell therapy that Vertex is developing in collaboration with CRISPR Therapeutics. In mid-2022, the global biotech firm further expanded its regenerative medicine portfolio with the US$320 million acquisition of ViaCyte and its stem cell-based type 1 diabetes treatment VCTX210, which is currently in Phase 1/2 clinical trials. Vertex Pharmaceuticals has developed a number of approved treatments for cystic fibrosis, and has a pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes. The companies below are listed in order of market cap size from biggest to smallest, with all numbers and figures current as of May 9, 2023. Here the Investing News Network profiles the 10 top stem cell companies listed on the NASDAQ. Looking at applications for stem cells, Markets and Markets estimates that the global stem cell therapy sector will reach a value of US$558.51 million by 2027, driven by "robust funding for stem cell research, an increase in the number of cell therapy production facilities that have GMP certification, and growth in the number of clinical trials associated with stem cell therapies." The stem cell market is expected to grow further via increased government funding for cancer research and the development of cellular therapies to treat various cancers. The research firm sees “the rising number of stem cell banks, growing focus on increasing therapeutic potential of these, and extensive research for the development of regenerative medicines” as drivers of this market. A report from Grand View Research projects that the global stem cell market will reach US$31.6 billion by 2030. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |